{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Attention+Control&page=12",
    "query": {
      "condition": "Attention Control",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 349,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Attention+Control&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Attention+Control&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T10:43:08.628Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02276209",
      "title": "Dasotraline Adult ADHD Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Dasotraline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 636,
      "start_date": "2014-12",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2017-08-28",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 59,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02276209"
    },
    {
      "nct_id": "NCT06447909",
      "title": "Randomized Controlled Trial of a Behavioral Training App",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Behavior, Child",
        "Disruptive Behavior",
        "Executive Dysfunction",
        "Attention-deficit",
        "Anxiety",
        "Depression",
        "Stress"
      ],
      "interventions": [
        {
          "name": "Treatment App",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Sham app",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "New York University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 100,
      "start_date": "2024-03-27",
      "completion_date": "2024-10-30",
      "has_results": false,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06447909"
    },
    {
      "nct_id": "NCT00640185",
      "title": "Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "ABT-089",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 160,
      "start_date": "2008-03",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 12,
      "location_summary": "Lafayette, California • Jacksonville, Florida • Orlando, Florida + 9 more",
      "locations": [
        {
          "city": "Lafayette",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00640185"
    },
    {
      "nct_id": "NCT00688376",
      "title": "Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Impairment"
      ],
      "interventions": [
        {
          "name": "Donepezil hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 72,
      "start_date": "2008-07-02",
      "completion_date": "2009-05-26",
      "has_results": true,
      "last_update_posted_date": "2022-01-05",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 13,
      "location_summary": "Stanford, California • Miami, Florida • Minneapolis, Minnesota + 10 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00688376"
    },
    {
      "nct_id": "NCT03769064",
      "title": "Study for Naltrexone on the Abuse Potential of Methylphenidate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Naltrexone",
        "Methylphenidate Abuse"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Methylphenidate 60 mg",
          "type": "DRUG"
        },
        {
          "name": "Treatment Phase Sequence 4213",
          "type": "DRUG"
        },
        {
          "name": "Treatment Phase Sequence 2134",
          "type": "DRUG"
        },
        {
          "name": "Treatment Phase Sequence 1342",
          "type": "DRUG"
        },
        {
          "name": "Treatment Phase Sequence 3421",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avekshan LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 94,
      "start_date": "2018-03-27",
      "completion_date": "2018-06-20",
      "has_results": false,
      "last_update_posted_date": "2018-12-07",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03769064"
    },
    {
      "nct_id": "NCT02327013",
      "title": "Investigating the Effect of Vortioxetine in Adult ADHD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "vortioxetine 10 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "vortioxetine 20 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 227,
      "start_date": "2014-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-03-07",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 15,
      "location_summary": "Beverly Hills, California • Garden Grove, California • National City, California + 11 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02327013"
    },
    {
      "nct_id": "NCT01364662",
      "title": "A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Impulsive Aggression Comorbid With ADHD"
      ],
      "interventions": [
        {
          "name": "SPN-810",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 121,
      "start_date": "2011-06",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 27,
      "location_summary": "Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01364662"
    },
    {
      "nct_id": "NCT01993212",
      "title": "A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Androxal 12.5 mg or 25 mg",
          "type": "DRUG"
        },
        {
          "name": "AndroGel 1.62%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repros Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2014-01",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-10-01",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 8,
      "location_summary": "Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01993212"
    },
    {
      "nct_id": "NCT03136263",
      "title": "Oxytocin and Cognitive Control in Adult ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Attention Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Oxytocin nasal spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo nasal spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2017-12-14",
      "completion_date": "2020-11-05",
      "has_results": false,
      "last_update_posted_date": "2024-05-03",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03136263"
    },
    {
      "nct_id": "NCT00799409",
      "title": "Lab School Day Study for CONCERTA of Older Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo/ CONCERTA (methylphenidate HCl)",
          "type": "DRUG"
        },
        {
          "name": "CONCERTA (methylphenidate HCl) / Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ortho-McNeil Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "9 Years to 12 Years"
      },
      "enrollment_count": 78,
      "start_date": "2008-12",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-10-22T10:43:08.628Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Houston, Texas",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00799409"
    }
  ]
}